One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial

Table 1

Baseline characteristics of the patients in two groups.

	1 + PRN	3 + PRN	P value
Patients (no.)	45	49
Age (mean ± SD)	69.7 ± 8.6	70.0 ± 8.8	0.855
Male/female	30/15	30/19	0.583
Right/left eye (no.)	28/17	25/24	0.274
Letters of BCVA (mean ± SD)	49.0 ± 16.2	52.0 ± 13.9	0.341
<30 letters (no.)	8	3	0.079
30–60 letters (no.)	27	33	0.459
>60 letters (no.)	10	13	0.629
CRT (μm, mean ± SD)	468 ± 202	428 ± 163	0.290
Eyes with PCV (%)	4 (8.9%)	4 (8.2%)	0.900
Pseudophakic	2	4	0.461
Patients with hypertension	10	12	0.795
Patients with diabetes	1	3	0.439
Hyperthyroidism	1	0	0.479

BCVA, best-corrected visual acuity; CRT, central retinal thickness; PCV, polypoidal choroidal vasculopathy; PRN, pro re nata; SD, standard deviation.